<DOC>
	<DOC>NCT00635856</DOC>
	<brief_summary>A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels</brief_summary>
	<brief_title>Open Label Trial to Assess Iressa in Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Prostate cancer diagnosis no evidence of metastasis Age 18 or older Prior chemotherapy for recurrent prostate cancer Radiotherapy completed within 28 days of starting the study Incomplete healing from prior cancer or other major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Iressa</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>PSA</keyword>
</DOC>